When Delay Became Unacceptable
A routine follow-up revealed progression that made the abstract threat suddenly concrete.
Eighteen months after his initial diagnosis, Owen returned to his primary care doctor for annual blood work. The results showed his liver enzymes had climbed higher—ALT now four times the upper limit of normal. His doctor ordered additional tests, including an ultrasound and a newer assessment called a FibroScan.
The ultrasound showed a slightly enlarged liver with increased echogenicity, suggesting fat accumulation and possible early scarring. The FibroScan—a non-invasive test measuring liver stiffness—indicated stage 2 fibrosis. Owen's doctor explained this meant significant scarring had developed, and without treatment, progression to cirrhosis was likely within the next decade.
The word 'cirrhosis' hit differently than 'elevated enzymes.' Owen knew cirrhosis meant liver failure, transplant lists, and shortened life expectancy. His doctor was direct: 'You have a curable infection that's damaging your liver. The treatment is simple—pills for 8-12 weeks with minimal side effects and a 95% cure rate. But we need to act before more damage occurs.'
That evening, Owen researched Hepatitis C treatment. He learned that modern direct-acting antivirals had revolutionized care—no more interferon injections, no debilitating side effects, just oral medication that cleared the virus in most patients. He also learned that curing the infection could halt fibrosis progression and even allow some reversal of scarring if caught early enough.
The distance to specialty care suddenly seemed trivial compared to the risk of doing nothing. Owen called the gastroenterology office the next morning.